Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21532298 | 0.94 | OPRD1 (0.32) | OPRD1KDM4EATML3MBTL1MEN1 | |
| SCHEMBL21532718 | 0.94 | OPRD1 (0.32) | OPRD1KDM4EATML3MBTL1MEN1 | |
| SCHEMBL21532258 | 0.93 | ALOX5 (0.35) | ALOX5PRKDCAKT1OPRD1GGPS1 | |
| SCHEMBL21532638 | 0.92 | ALOX5 (0.33) | ALOX5PRKDCAKT1OPRD1GGPS1 | |
| SCHEMBL23911751 | 0.92 | ALOX5 (0.34) | ALOX5PRKDCAKT1GGPS1MEN1 | |
| SCHEMBL21532245 | 0.92 | ALOX5 (0.34) | ALOX5PRKDCAKT1GGPS1MEN1 | |
| SCHEMBL21532549 | 0.92 | AKT1 (0.35) | ALOX5PRKDCAKT1 | |
| SCHEMBL21532548 | 0.91 | ALOX5 (0.35) | ALOX5PRKDCAKT1OPRD1GGPS1 | |
| SCHEMBL21532573 | 0.91 | ALOX5 (0.35) | ALOX5PRKDCAKT1OPRD1GGPS1 | |
| SCHEMBL21532277 | 0.90 | ALOX5 (0.32) | ALOX5PRKDCAKT1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-10-12 | — | — | US | disclosed |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | CRY1, CCNT1, CCNA1 | ALOX5 3170/4885PRKDC 4851/4885AKT1 2105/4885 |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, ARL1 | ALOX5 2800/4885PRKDC 4874/4885AKT1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.